Search research articles
Contact Us
Filters
Showing results (1-10 of 36) with videos related to
Page
of 4
Sort By:
Revue Medicale Suisse
|
February 20, 2025
Joachim Marti, Niklaus Meier
JAMA Neurology
|
April 12, 2016
Keeping an Eye on This Headache
Matthias Hoheisel, Matthias Sturzenegger, Niklaus Meier
Statistics in Medicine
|
May 19, 2026
Comment on "Meta-Analysis of Cost-Effectiveness" by Bang and Zhao: Combinability, Joint Modeling, and a Two-Stage Framework for Cost-Effectiveness Analysis Synthesis
Gian Luca Di Tanna, Niklaus Meier, Matthias Schwenkglenks
Swiss Medical Weekly
|
October 28, 2024
Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland
Maria Trottmann, Eva Blozik, Marcel Hilbig, et al.
Neurology
|
February 5, 2022
Clinical Reasoning: A Dizzy Architect
Adrian Scutelnic, Aikaterini Galimanis, Michael Horn, et al.
Journal of Medical Economics
|
December 18, 2024
Systematic review of cost-effectiveness modelling studies for haemophilia
Niklaus Meier, Daniel Ammann, Mark Pletscher, et al.
Pharmacoeconomics
|
November 10, 2025
Individualized Treatment Rules Based on Cost-Effectiveness Criteria in Microsimulations
Niklaus Meier, Ana Cecilia Quiroga Gutierrez, Mark Pletscher, et al.
Lancet (London, England)
|
April 30, 2013
Cervical polyradiculopathy caused by vertebral artery dissection
Franca Wagner, Marie-Luise Mono, Harold Köndgen, et al.
Pharmacoeconomics - Open
|
March 23, 2024
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, et al.
Pharmacoeconomics
|
August 12, 2023
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
Michaela Carla Barbier, Alicia Fengler, Esther Pardo, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 36) with videos related to
Sort By:
Page
of 4
Revue Medicale Suisse
|
February 20, 2025
Joachim Marti, Niklaus Meier
JAMA Neurology
|
April 12, 2016
Keeping an Eye on This Headache
Matthias Hoheisel, Matthias Sturzenegger, Niklaus Meier
Statistics in Medicine
|
May 19, 2026
Comment on "Meta-Analysis of Cost-Effectiveness" by Bang and Zhao: Combinability, Joint Modeling, and a Two-Stage Framework for Cost-Effectiveness Analysis Synthesis
Gian Luca Di Tanna, Niklaus Meier, Matthias Schwenkglenks
Swiss Medical Weekly
|
October 28, 2024
Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland
Maria Trottmann, Eva Blozik, Marcel Hilbig, et al.
Neurology
|
February 5, 2022
Clinical Reasoning: A Dizzy Architect
Adrian Scutelnic, Aikaterini Galimanis, Michael Horn, et al.
Journal of Medical Economics
|
December 18, 2024
Systematic review of cost-effectiveness modelling studies for haemophilia
Niklaus Meier, Daniel Ammann, Mark Pletscher, et al.
Pharmacoeconomics
|
November 10, 2025
Individualized Treatment Rules Based on Cost-Effectiveness Criteria in Microsimulations
Niklaus Meier, Ana Cecilia Quiroga Gutierrez, Mark Pletscher, et al.
Lancet (London, England)
|
April 30, 2013
Cervical polyradiculopathy caused by vertebral artery dissection
Franca Wagner, Marie-Luise Mono, Harold Köndgen, et al.
Pharmacoeconomics - Open
|
March 23, 2024
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, et al.
Pharmacoeconomics
|
August 12, 2023
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
Michaela Carla Barbier, Alicia Fengler, Esther Pardo, et al.
Page
of 4